Diakonos Oncology Corp. (“Diakonos”), a company in the clinical stage of immuno-oncology, has announced today the appointment of Dr. Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, to its Board of Directors.
According to Mike Wicks, Chief Executive Officer of Diakonos, “Dr. Lammers’ success in leading both private and public biopharma companies, combined with his extensive experience in fundraising, will provide critical experience in guiding our clinical development and commercialization of Diakonos’ unique cancer immunotherapies.” Wicks further emphasized Dr. Lammers’ pivotal role in advancing cell therapies for cancer, which aligns perfectly with Diakonos’ mission to revolutionize the treatment landscape for patients facing the most challenging cancers.
Dr. Lammers is renowned for his strategic leadership and successful fundraising efforts, notably during his tenure as President and CEO of Triumvira Immunologics, where he secured substantial venture funding focusing on CAR T-cell therapies for solid tumors. Prior to his role at Triumvira, he served as President and CEO of Mirna Therapeutics, leading the company to its public listing on NASDAQ in 2015. His previous positions include Chief Medical Officer and Head of US Product Development at EMD Serono, where he managed a large team of professionals, and various executive roles that showcased his expertise in clinical development, medical, and regulatory affairs across the pharmaceutical and biotech sectors.
Expressing his sentiments about joining Diakonos, Dr. Lammers stated, “I am deeply honored to join the Diakonos team and contribute to their groundbreaking work in developing dendritic cell vaccines. This technology represents a significant leap forward in cancer treatment, promising a new era of personalized and effective immunotherapies for patients in dire need.
